ERBB2 and breast carcinoma: In HER2+ breast cancer, the addition of T to standard neoadjuvant chemotherapy significantly improved both, pathological complete response rates and event-free survival (defined as: time from randomization to disease recurrence or progression): 71% versus 56% at 3 years; Hazard Ratio (HR) = 0.59, p = 0.013) [11].